

Wilhelmus J Kwanten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2143062/publications.pdf>

Version: 2024-02-01

19
papers

1,132
citations

623188

14
h-index

887659

17
g-index

20
all docs

20
docs citations

20
times ranked

2299
citing authors

#	ARTICLE	IF	CITATIONS
1	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
2	Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD. <i>JHEP Reports</i> , 2022, 4, 100412.	2.6	12
3	Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. <i>Journal of Hepatology</i> , 2021, 75, 292-301.	1.8	68
4	Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?" <i>Journal of Hepatology</i> , 2021, 75, 1513-1514.	1.8	0
5	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. <i>Frontiers in Immunology</i> , 2020, 11, 1711.	2.2	19
6	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 467-490.	2.3	26
7	Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. <i>Nature Biomedical Engineering</i> , 2020, 4, 801-813.	11.6	34
8	Portal Hypertension in NASH: Is It Different from Other Aetiologies?. <i>Current Hepatology Reports</i> , 2019, 18, 134-143.	0.4	1
9	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. <i>Frontiers in Immunology</i> , 2019, 10, 82.	2.2	157
10	Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?. <i>Obesity Reviews</i> , 2019, 20, 353-363.	3.1	42
11	The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2019, 122, 188-197.	0.8	25
12	Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. <i>Laboratory Investigation</i> , 2018, 98, 1263-1275.	1.7	33
13	Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events. <i>Clinical Cancer Research</i> , 2018, 24, 3803-3812.	3.2	40
14	Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors. <i>Hepatology</i> , 2017, 66, 252-265.	3.6	35
15	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G599-G609.	1.6	37
16	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. <i>Journal of Hepatology</i> , 2016, 65, 425-443.	1.8	366
17	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7325.	1.4	88
18	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. <i>Laboratory Investigation</i> , 2012, 92, 1428-1439.	1.7	100

#	ARTICLE	IF	CITATIONS
19	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD). , 0, , .		7